Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
24
CLPBF Quote, Financials, Valuation and Earnings
Last price:
$66.48
Seasonality move
:
-0.21%
Day range:
$66.48 - $66.48
52-week range:
$66.48 - $106.80
Dividend yield:
5.36%
P/E ratio:
24.74x
P/S ratio:
3.55x
P/B ratio:
6.90x
Volume:
--
Avg. volume:
964
1-year change:
-35.78%
Market cap:
$15B
Revenue:
$4.1B
EPS (TTM):
$2.69
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Coloplast A/S has -- downside to fair value with a price target of -- per share.
CLPBF vs. S&P 500
-
Over the past 5 trading days, Coloplast A/S has underperformed the S&P 500 by -3.25% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Coloplast A/S does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Coloplast A/S has grown year-over-year revenues for 22 quarters straight. In the most recent quarter Coloplast A/S reported revenues of $1.1B.
Earnings Growth
-
Coloplast A/S has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Coloplast A/S reported earnings per share of $0.97.
Enterprise value:
18.8B
EV / Invested capital:
--
Price / LTM sales:
3.55x
EV / EBIT:
16.48x
EV / Revenue:
4.44x
PEG ratio (5yr expected):
13.87x
EV / Free cash flow:
21.78x
Price / Operating cash flow:
17.41x
Enterprise value / EBITDA:
13.78x
Gross Profit (TTM):
$2.9B
Return On Assets:
8.26%
Net Income Margin (TTM):
14.35%
Return On Equity:
25.46%
Return On Invested Capital:
10.28%
Operating Margin:
26.18%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $3.6B | $4B | $4.2B | $1B | $1.1B | |
| Gross Profit | $2.4B | $2.7B | $2.9B | $679.3M | $737.9M | |
| Operating Income | $992.7M | $1.1B | $1.1B | $272.9M | $287.4M | |
| EBITDA | $1.2B | $1.3B | $1.4B | $319.8M | $341.1M | |
| Diluted EPS | $3.26 | $3.15 | $2.69 | $0.66 | $0.97 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.1B | $1.3B | $1.5B | $1.4B | $1.6B | |
| Total Assets | $2.5B | $5.4B | $7.2B | $6.7B | $7.7B | |
| Current Liabilities | $1.3B | $1.5B | $2.8B | $1.8B | $1.2B | |
| Total Liabilities | $1.5B | $4.6B | $5B | $4.6B | $5.5B | |
| Total Equity | $981.5M | $847.5M | $2.2B | $2.1B | $2.2B | |
| Total Debt | $91.9M | $2.5B | $2.6B | $1.7B | $3.4B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $808.2M | $431M | $1.1B | $287M | $348M | |
| Cash From Investing | -$1.3B | -$174.9M | -$241.3M | -$19M | -$64.2M | |
| Cash From Financing | $545.2M | -$259.2M | -$819.6M | -$251.8M | -$255.9M | |
| Free Cash Flow | $624.9M | $230.8M | $860.8M | $243M | $283.5M | |
CLPBF
Sector
Market Cap
$15B
$23.9M
Price % of 52-Week High
62.25%
47.44%
Dividend Yield
5.36%
0%
Shareholder Yield
3.66%
-1.88%
1-Year Price Total Return
-35.78%
-18.29%
Beta (5-Year)
0.967
0.513
Dividend yield:
5.36%
Annualized payout:
$3.16
Payout ratio:
463.6%
Growth streak:
3 years
Technicals
8-day SMA
Sell
Level
$66.61
200-day SMA
Sell
Level
$87.27
Bollinger Bands (100)
Sell
Level
73.04 - 90.4
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$68.17
Relative Strength Index (RSI14)
Sell
Level
10.14
ADX Line
Sell
Level
58.91
Williams %R
Buy
Level
-100
50-day SMA
Sell
Level
$74.66
MACD (12, 26)
Buy
Level
14.66
25-day Aroon Oscillator
Sell
Level
-76
On Balance Volume
Sell
Level
-1.1K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.8872)
Buy
CA Score
(Annual)
Level (-0.2402)
Buy
Beneish M-Score
(Annual)
Level (-2.7014)
--
Momentum Score
Level (--)
Buy
Ohlson Score
Level (0.3794)
Buy
Piotroski F Score
(Annual)
Level (6)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (10)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Coloplast A/S engages in the developing, manufacture, and markets medical products. It operates through the following segments: Chronic Care, Voice and Respiratory Care, Interventional Urology, Advanced Wound Dressings, and Biologics. The Chronic Care segment covers the sale of ostomy care products and continence care products. The Voice and Respiratory Care segment refers to the sale of laryngectomy and tracheostomy products. The Interventional Urology segment includes the sale of urological products, including disposable products. The Advanced Wound Dressings segment focuses on the sale of wound and skin care products. The Biologics segment represents a new segment covering the sale of tissue-based products. The company was founded by Aage Louis-Hansen and Johanne Louise-Hansen in 1954 and is headquartered in Humlebaek, Denmark.
Stock Forecast FAQ
In the current month, CLPBF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CLPBF average analyst price target in the past 3 months is --.
-
Where Will Coloplast A/S Stock Be In 1 Year?
According to analysts, the consensus estimate is that Coloplast A/S share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Coloplast A/S?
Analysts are divided on their view about Coloplast A/S share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Coloplast A/S is a Sell and believe this share price will rise from its current level to --.
-
What Is Coloplast A/S's Price Target?
The price target for Coloplast A/S over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CLPBF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Coloplast A/S is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of CLPBF?
You can purchase shares of Coloplast A/S via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Coloplast A/S shares.
-
What Is The Coloplast A/S Share Price Today?
Coloplast A/S was last trading at $66.48 per share. This represents the most recent stock quote for Coloplast A/S. Yesterday, Coloplast A/S closed at $66.48 per share.
-
How To Buy Coloplast A/S Stock Online?
In order to purchase Coloplast A/S stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get CLPBF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CLPBF
Sector
P/E ratio
24.74x
21.37x
PEG ratio
13.87x
-0.01x
P/B ratio
6.90x
1.72x
Price / LTM sales
3.55x
1.45x
Growth Metrics
CLPBF
Sector
Revenue growth
9.24%
3.44%
Earnings growth
45.78%
15.03%
Revenue (5-year growth)
8.2%
6.25%
Earnings forecast
--
-$0.22
Profitability
CLPBF
Sector
Profitability FY 2025
$2.7B
$2.4M
Return on invested capital
10.28%
-33.32%
Return on assets
8.26%
-29.45%
Return on equity
25.46%
-40.29%
Earnings Date
Last Earnings Date
Feb
6
Next Earnings Date
May
12
Estimated Next Earnings Date
May
8
Balance Sheet
CLPBF
Sector
Total cash
$176.9M
$25.7M
Short term investments
--
$22.7M
Total assets
$7.6B
$70.6M
Long term debt
$3.4B
$2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 3
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 3
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 3
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
